Immutep Limited – LifeCareNews

LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283

Immutep Announces Successful Meeting with the FDA on

Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patientsPatient population expanded to include patients with…

Immutep to Participate in The JMP Securities Hematology and

Media Release SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and…

Immutep Announces Abstract Highlighting Eftilagimod Alpha

Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference Company to host Webcast on Thursday, 10th November at 5 PM ET to discuss data in…